He recalled being 'so scared' and wondering if he was ever 'going to be able to walk again' after the 2013 diagnosis.

There’s a spring in former Carson High School teacher Phil Brady’s step now that he doesn’t have to rely on his wheelchair ...

Could NfL and GFAP redefine how clinicians track progression in MS? Dr Mark Freedman joins Dr Anne Cross to explain the ...

Treatment with fenebrutinib in a 2-year open-label extension study led to significantly reduced disease-related inflammatory activity in those with relapsing MS, according to speaker at ECTRIMS ...

In a cohort of Black and Hispanic individuals with relapsing MS, baseline comorbidities had no significant effect on the ...

After her MS diagnosis, Becky was worried her kids would have to care for her, but a stem cell transplant has changed the ...

Too often, young people with serious illnesses are dismissed or told they’re “too young” to be sick – and Independent readers have been sharing their own experiences of being ignored by the NHS. Our ...

Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas BioP ...

The integration of Cortechs.ai’s NeuroQuant® solutions on Philips MR systems via Smart Reading is works in progress and not available in any jurisdiction. Its future availability cannot be ensured.

Fischer Medical Ventures Limited (FISCHER | 524743 | INE771F01041), a leading innovator in medical imaging and diagnostic solutions, has announced the appointment of Dr. Iype Cherian, globally ...

Health technology company Royal Philips announced an extended partnership with Cortechs.ai, a company specializing in ...